ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial

Boussofara, Amine; Laroussi, Lobna; Baccouche, Héla; Bennour, E.; Kasbaoui, Sami; Triki, Hbib; Zied, Ibn El Haj; Kammoun, Ikram; Halima, Afef Ben; Addad, Faouzi; Marrakchi, S.; Romdhane, Neïla Ben; Kachboura, Salem

doi:10.1007/s00228-020-02969-y

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, our findings suggest a slightly increased in vivo thrombin generation immediately following strenuous exercise, but following 2 h of recovery, both ex vivo and in vivo thrombin generation were reduced in patients with CAD. Aspirin treatment may reduce thrombin generation parameters [29], but the effect seems to be more evident on aspirin dosage above 100 mg daily [30]. In our study, ETP and F1 + 2 did not differ between CAD patients and healthy individuals; however, 2 h after strenuous exercise, ETP and F1 + 2 decreased in CAD patients alone.…”

Section: Discussioncontrasting

confidence: 66%

Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease

Kristiansen,

Grove,

Sjúrðarson

et al. 2024

Thrombosis Research

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 66%

Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease

Kristiansen,

Grove,

Sjúrðarson

et al. 2024

Thrombosis Research

View full text Add to dashboard Cite

“…All the patients receiving anti platelet therapy, whose ABR was the highest within the group, displayed reduced TG at maintenance, regardless of their emicizumab levels. Notably reduced TG (even when performed on PPP) in patients receiving antiplatelet therapy was previously reported 26,27 ; thus, the interpretation of TG findings as a potential predictor of bleeding tendency is limited. In general, variability of TG measurements was noted among our HIV patients.…”

Section: Discussionmentioning

confidence: 91%

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data

Misgav

Brutman‐Barazani

Budnik³

et al. 2021

Haemophilia

View full text Add to dashboard Cite

Introduction: Emicizumab (Hemlibra™) is approved for prophylaxis of Haemophilia A (HA) patients with and without inhibitors. However, real-world data on emicizumab use in the elderly HA patients with concomitant cardiovascular risk factors are lacking. Aim: To evaluate the safety and efficacy of emicizumab in a real-world cohort of elderly HA patients. Methods: A prospective longitudinal observational study on HA patients over 50 years old treated, followed and monitored during emicizumab prophylaxis was conducted. We documented any bleeding or adverse events and collected plasma samples for emicizumab levels, aPTT and thrombin generation (TG). Results: Seventeen HA patients (2 with inhibitor), whose median age was 62.4 years (range: 51.5-77.1) composed the cohort, including 9/17 with multiple cardiovascular risk factors (high risk group). Seven patients had chronic HIV infection. The median follow-up of our cohort was 400 days (range 89-805, IQR 211-479 days). The median annualized bleeding rate (ABR) significantly decreased for all patients. Among patients who displayed significant bleeding tendencies, emicizumab steady state levels as well as TG were lower as compared with the group. The ABR of four patients concomitantly treated by antiplatelet agents was significantly higher compared with the rest of the cohort. Neither thrombosis nor thrombotic microangiopathy (TMA) was encountered. Conclusions: Emicizumab prophylaxis for HA patients older than 50 years including those with cardiovascular risk factors was well tolerated. As lower emicizumab and TG levels were observed among bleeding patients, we suggest that monitoring laboratory assays could be of value within this age group.

show abstract

ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial

Cited by 2 publications

References 42 publications

Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease

Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data

Contact Info

Product

Resources

About